Overview

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.
Phase:
N/A
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Aprepitant
Fosaprepitant